Rhode Island

Rhode Island’s politics here are persistent rather than transformative. In 2023 the House passed H5923A, which would have decriminalised small-scale possession and home cultivation and tied future therapeutic use to FDA action. In 2024, H7047 continued the same approach. In 2026 the concept returned in two new House bills, H7756 and H7925, both framed around limited exemptions and contingent Department of Health rulemaking in the event of federal change. None of those bills created a current patient pathway.###

A separate 2026 development worth watching is S3184, a nursing/sedation bill rather than a psychedelic bill. Practitioner testimony argued it could unintentionally restrict access to ketamine-assisted psychotherapy delivered by non-CRNA advanced practice clinicians. The Senate calendar and journal show the original bill was indefinitely postponed and Substitute A passed the Senate on 7 May 2026. That does not create psychedelic access, but it could affect workforce and care-delivery models around ketamine.###

Rhode Island’s most credible research node is the Brown/Butler/Providence VA orbit, but it is still narrower than the state’s legislative visibility might suggest. Brown-associated investigators published Rhode Island-based ketamine work on suicidal ideation, and VA announced in late 2024 that researchers affiliated with Brown University and Yale would lead the VA’s first study of psychedelic-assisted therapy for veterans, focused on MDMA-assisted therapy for PTSD and alcohol use disorder.###

Butler Hospital also ran an esketamine study that is now closed and continues to provide esketamine clinically. That makes Rhode Island a meaningful ketamine/esketamine state in academic psychiatry terms, even though it does not yet have a broad portfolio of publicly visible classical-psychedelic trials.###

Because there is no enacted psilocybin statute, there is no implementation machinery for service centres, facilitator licensing or state psychedelic training. The only implementation language in the 2026 psilocybin bills is future-dependent and expressly conditioned on FDA rescheduling and access expansion.###

The implementation issue that matters now is conventional care delivery. Butler’s esketamine model sits inside ordinary psychiatric services and the federal REMS regime. Separately, the S3184 debate shows how licensing and sedation rules for nurses can become unexpectedly important for ketamine-assisted psychotherapy availability even without any psychedelic-specific reform.###

The verified ecosystem is anchored by Butler Hospital, Brown University-linked researchers and the Providence VA research network rather than by a large commercial psychedelic-services sector. Butler is the clearest clinical site; Brown provides research and public-health credibility; and the VA-funded MDMA study announcement materially raises Rhode Island’s profile in veteran-focused psychedelic research.###

Policy advocacy is also more developed than in many states, with repeated bills from the same legislative coalition, but that political activity should not be mistaken for a functioning access market. Rhode Island is better described as “policy-active, access-limited, research-selective”.###

Over the next 12 to 24 months, Rhode Island is likely to remain a policy watcher state rather than an implementation state. The recurring psilocybin bills show sustained interest, but their design is expressly contingent on federal developments and therefore unlikely to produce immediate in-state patient access on their own.###

The more immediate practical question is whether Rhode Island’s clinical workforce rules will support or constrain ketamine-assisted psychotherapy, and whether the Brown/VA research thread generates additional local trial activity. Evidence development may outpace policy implementation.###